Sucampo Pharma Americas, LLC
Quick facts
Phase 3 pipeline
- Cohort 1: Lubiprostone Capsule, Fasted · Gastroenterology
Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel motility. - Lubiprostone 24 · Gastroenterology
Lubiprostone is a ClC-2 chloride channel activator that increases intestinal fluid secretion and promotes bowel motility to relieve constipation.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Sucampo Pharma Americas, LLC
What is Sucampo Pharma Americas, LLC's pipeline?
Sucampo Pharma Americas, LLC has 2 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include Cohort 1: Lubiprostone Capsule, Fasted, Lubiprostone 24.
Related
- Sector hub: All tracked pharma companies